About Glycosan
Glycosan is a Healthcare company based in Alameda (United States) founded in 2006, and was acquired by Lineage Cell Therapeutics in February 2011. Biocompatible hydrogels mimicking extracellular matrix are developed for tissue engineering. It operates in the Healthcare and Chemicals & Materials sectors. Glycosan has raised $950 thousand across 5 funding rounds from investors including Lineage Cell Therapeutics and HHS. Its focus areas include High Tech, Advanced Materials, Biomaterials and Biomimetics. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Glycosan was founded in 2006 in Alameda, United States, focusing on biotechnology for regenerative medicine and tissue engineering. Biocompatible hydrogels, including the proprietary Extracel technology, are created to support stem cell growth and differentiation. These materials serve as implantable, resorbable matrices. The company was acquired by BioTime in February 2011, integrating its operations into broader stem cell research efforts.
- Headquarters Alameda, United States
- Stage Acquired
- SectorsHealthcareChemicals & Materials
- Website glycosan.com
- Social LinkedIn
- Acquired by Lineage Cell Therapeutics (Feb 2011)
- Total Equity Funding$950K (USD)
in 5 rounds
- Latest Funding Round$625K (USD), Seed
May 2010
- InvestorsLineage Cell Therapeutics
& 1 more
- Acquired byLineage Cell Therapeutics
(Feb 2011)
Funding Insights of Glycosan
Glycosan has successfully raised a total of $950K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $625 thousand completed in May 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $950,000
- Total Rounds 5
- Last Round Seed — $625,000
- First Round $325,000
(Jul 2009)
- Investors Count 1
All 5 funding rounds of Glycosan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Glycosan
Glycosan has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Lineage Cell Therapeutics and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Lineage Cell Therapeutics is focused on developing allogeneic cell therapies. | 1990 | lineagecell.com | Carlsbad, United States |
Investor details for Glycosan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Glycosan
4 dated milestones of Glycosan across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Glycosan is founded.
- Funding First funding round of $325K.
- Funding Latest funding round, Seed, of $625K.
- Exit Acquired by Lineage Cell Therapeutics.
Competitors of Glycosan
Glycosan has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of Glycosan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Glycosan
Websites that share an audience with Glycosan (glycosan.com).
Websites whose visitors overlap most with Glycosan. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biolamina.com | 100% | 9.1K | #2,560,936 | View details | |
| celprogen.com | 98% | #3,394,353 | View details | ||
| invitria.com | 96% | #3,790,077 | View details | ||
| celartia.com | 96% | #10,202,963 | View details | ||
| advancedbiomatrix.com | 96% | 22.2K | #1,316,716 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Glycosan
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Glycosan (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glycosan
Complete news archive for Glycosan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glycosan
Glycosan was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Glycosan is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Glycosan is a funded company, having raised a total of $950K across 5 funding rounds to date. The company's 1st funding round was a Seed of $325K, raised on Jul 2009.
Glycosan was founded in 2006 in Alameda, United States, focusing on biotechnology for regenerative medicine and tissue engineering. Biocompatible hydrogels, including the proprietary Extracel technology, are created to support stem cell growth and differentiation. These materials serve as implantable, resorbable matrices. The company was acquired by BioTime in February 2011, integrating its operations into broader stem cell research efforts.
Glycosan's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Glycosan has 2 investors. Key investors include Lineage Cell Therapeutics, and HHS.
Yes. Glycosan was acquired by Lineage Cell Therapeutics in February 2011.